“AUTM’s recognition of Dr. Peter Tsai and Dr. Michael Whitt emphasizes the high-caliber research and technology coming out of the UT System…”, UTRF President Dr. Stacey Patterson.
UTRF in the News
UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer
A Mission for Making Good Medicine The University of Tennessee Research Foundation (UTRF), the University of Tennessee Health Science Center (UTHSC), and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel treatment with promising efficacy against pancreatic cancer tumors. According to the Genetic and Rare Diseases Information Center, the total number of (read more)
UTRF Licensee Announces Positive Phase 2 Clinical Results of VERU-111 for COVID-19
UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day (read more)